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Abstract
Natural progression of HIV-1 infection depends on genetic variation in the human major histocompatibility complex (MHC)
class I locus, and the CD8
+ T cell response is thought to be a primary mechanism of this effect. However, polymorphism
within the MHC may also alter innate immune activity against human immunodeficiency virus type 1 (HIV-1) by changing
interactions of human leukocyte antigen (HLA) class I molecules with leukocyte immunoglobulin-like receptors (LILR), a
group of immunoregulatory receptors mainly expressed on myelomonocytic cells including dendritic cells (DCs). We used
previously characterized HLA allotype-specific binding capacities of LILRB1 and LILRB2 as well as data from a large cohort of
HIV-1-infected individuals (N=5126) to test whether LILR-HLA class I interactions influence viral load in HIV-1 infection. Our
analyses in persons of European descent, the largest ethnic group examined, show that the effect of HLA-B alleles on HIV-1
control correlates with the binding strength between corresponding HLA-B allotypes and LILRB2 (p=10
22). Moreover,
overall binding strength of LILRB2 to classical HLA class I allotypes, defined by the HLA-A/B/C genotypes in each patient,
positively associates with viral replication in the absence of therapy in patients of both European (p=10
211–10
29) and
African (p=10
25–10
23) descent. This effect appears to be driven by variations in LILRB2 binding affinities to HLA-B and is
independent of individual class I allelic effects that are not related to the LILRB2 function. Correspondingly, in vitro
experiments suggest that strong LILRB2-HLA binding negatively affects antigen-presenting properties of DCs. Thus, we
propose an impact of LILRB2 on HIV-1 disease outcomes through altered regulation of DCs by LILRB2-HLA engagement.
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HIV-1 disease progression is influenced by host genetic factors
and varies greatly among infected individuals. Polymorphism in
the HLA class I locus has been consistently shown to associate with
HIV-1 infection outcomes by both the candidate gene approach
[1] and genome-wide association studies [2,3]. The influence of
specific HLA class I alleles on HIV-1 disease is particularly obvious
for HLA-B alleles, among which HLA-B*57 and -B*27 exhibit
consistent protective effects [4,5,6,7] and an allelic group called
HLA-B*35-Px associates with accelerated disease progression [8].
HLA class I involvement in HIV-1 disease is primarily thought
to be linked to cytotoxic CD8
+ T lymphocyte (CTL) responses,
which are restricted by the host’s class I allotypes [9,10]. However,
alternative mechanisms may exist, given the fact that the HLA
class I molecules represent important ligands for receptors
regulating activities of innate immune cells. These include the
killer cell immunoglobulin-like receptors (KIRs) and leukocyte
immunoglobulin-like receptors (LILRs). Members of both receptor
families have been implicated in anti-HIV immunity. For instance,
certain combinations of HLA-B and KIR3DL/S1 alleles encoding
receptor-ligand pairs associate with slower disease progression,
which may be due to increased natural killer cell responsiveness to
infected cells [11,12]. In addition, a strong LILRB2-HLA-B*35-Px
interaction is suggested to impair dendritic cell (DC) function
during HIV-1 infection, possibly leading to faster disease
progression [13]. Down-modulation of DC function was also
observed as a result of a stronger interaction between LILRB2 and
HLA-B*27 loaded with the viral escape mutant KK10 L6M
compared to the wild type peptide loaded complex [14].
LILRB1 and LILRB2 are the most well-studied members of the
LILR family [15,16]. These two receptors share 82% sequence
homology and bind both classical and non-classical HLA class I
molecules [17,18]. LILRB2 is exclusively expressed on cells of the
myeloid lineage, including conventional DCs, whereas LILRB1
can also be expressed by lymphoid cells. Upon ligand engagement,
LILRB1 and LILRB2 induce inhibitory signals via immunor-
eceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplas-
mic tails. Thus, these inhibitory receptors, whose ligands are
ubiquitously expressed, might play a role in elevating the
activation threshold of the myelomonocytic cells and preventing
self-damage. LILRB1/B2 interactions with HLA class I involve
b2-microglobulin (b2m) and the a3 domain of the class I molecule,
which are relatively conserved across allotypes [19,20,21]. A
recent study demonstrated variability in binding of LILRB1- and
LILRB2-Fc fusion proteins to individual class I allotypes, which
included 31 HLA-A, 47 HLA-B and 16 HLA-C allotypes,
indicating that additional regions of HLA class I molecules are
involved in the interaction [22]. Compared to LILRB1, LILRB2
showed a greater degree of variability in binding to HLA allotypes.
Notably, HLA-B*57:01 and -B*27:05, which associate with
protection in HIV/AIDS, were among the weakest LILRB2
binders. Such a low binding level may reduce inhibitory effects of
LILRB2 in DCs and thus contribute to the protective effect of the
corresponding alleles.
Based on these findings, we hypothesized that the differential
LILRB1/2-HLA binding may impact overall immune response to
HIV-1 through modification of DC function and thus influence
HIV-1 disease outcomes. Specifically, HLA molecules that bind
more strongly to LILRB2 were predicted to blunt DC function,
which may ultimately contribute to reduced immune control of
viral replication and more rapid disease progression. To test this
hypothesis, we used epidemiological and HLA genotyping data
from several natural history cohorts of HIV-1-infected persons and
analyzed clinical outcomes in these patients in relation to in vitro
determined levels of interactions between individual HLA class I
allotypes and LILRB1/B2. Our data suggest that the binding
strength between LILRB2 and HLA may contribute to HIV-1
control.
Results
Effect of HLA-B on viral control correlates with the LILRB2
binding strength
To evaluate the influence of LILR-HLA interactions on HIV-1
disease, we tested for a potential correlation between LILR-HLA
binding level and the strength of HLA allelic associations with viral
control. Previously defined binding scores for HLA class I allotypes
(Table S1) were used as a measure of LILR-HLA binding strength
(Material and Methods, [22]). We compared the distribution of the
HLA alleles in HIV-1 controllers and noncontrollers, all in the
absence of therapy. Controllers were defined as individuals whose
longitudinal mean viral load (mVL) remained below 2,000 copies
per ml of plasma in the absence of therapy, whereas noncontrollers
were patients whose mVL exceeded 10,000 copies per ml. Odds
ratios (ORs) were calculated for each HLA allele using a univariate
logistic regression model (Table S1), and significant ORs (p,0.05)
were tested for correlations with the LILRB1/B2 binding scores in
patients of European and African descent (referred to as whites
and blacks, respectively). No relationship was found between the
strength of LILRB1-HLA binding scores and the ORs of the
corresponding alleles (Table S2). However, LILRB2 binding
strength to HLA-B demonstrated a significant positive correlation
with the ORs of the respective alleles in white patients (r=0.64,
p=0.01; Table 1 and Figure 1). The correlation in our smaller
cohort of black patients occurred in the same direction, but did not
reach significance (r=0.24, p=0.6). Permutation analyses indi-
cated that the significant positive correlation in whites is unlikely to
have occurred by chance (p=0.03). This finding suggests that the
interaction between HLA-B and LILRB2 may participate in the
overall effect of HLA-B alleles on HIV-1 control, where weaker
binding of a given HLA-B allotype to LILRB2 correlates with
greater protection of the corresponding allele, possibly as a
consequence of enhanced DC function.
LILRB2 binding strength to HLA class I correlates with
viral load in HIV-1 infection
A more rigorous test for an effect of LILRB2 on HIV-1
outcomes was performed by assigning to each patient four
LILRB2-related scores, three locus-specific (A, B, C for HLA-A,
-B and -C, respectively) scores and one combined (ABC) score,
based on each patient’s class I genotype, and then correlating these
Author Summary
Leukocyte immunoglobulin-like receptors B1 and B2
(LILRB1 and LILRB2) bind HLA class I allotypes with variable
affinities. Here, we show that the binding strength of
LILRB2 to HLA class I positively associates with level of
viremia in a large cohort of untreated HIV-1-infected
patients. This effect appears to be driven by HLA-B
polymorphism and demonstrates independence from class
I allelic effects on viral load. Our in vitro experiments
suggest that strong LILRB2-HLA binding negatively affects
antigen-presenting properties of dendritic cells (DCs).
Thus, we propose an impact of LILRB2 on HIV-1 immune
control through altered regulation of DCs by LILRB2-HLA
engagement.
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patient. Locus-specific scores were generated as a sum of binding
scores corresponding to the two alleles at each locus to reflect
average LILRB2 binding. The combined ABC binding score was
a sum of A, B and C scores, but for HLA-C, only 1/10 of the sum
was incorporated into the final score since HLA-C is known to be
expressed on the cell surface at roughly 1/10 the level of HLA-A
and -B [23]. This combined score, which was used as a measure of
average LILRB2 binding to class I on the cell surface, may be
more relevant to the physiological consequences of the LILRB2
ligation than the locus-specific scores, since LILRB2 binds to all
HLA-A, -B and -C allotypes [17,22]. Notably, the variation in the
B binding scores appears to be the main contributor to the
variation of the ABC scores at the population level (Figure 2),
given the relatively small range of the A scores and low 10%
contribution of the C scores.
A significant positive correlation of the LILRB2-ABC binding
scores with mVL used as a continuous variable was observed in
both white and black patients using a univariate model (r=0.21,
p=3 610
230 and r=0.14, p=5610
28, respectively; Table 2).
Locus specific analyses indicated that this correlation is driven
mainly by the B scores (r=0.24, p=1610
238 in whites and
r=0.16, p=6610
210 in blacks), since A scores show no significant
correlation and C scores actually trend in the opposite direction,
where higher binding of HLA-C to LILRB2 confers slight
protection.
To confirm that the LILRB2-HLA binding effect on HIV-1
disease outcomes is independent of the effects of individual class I
alleles that are not related to LILRB2 binding, we used regression
models with stepwise selection with p,0.05 as a threshold for
inclusion, which included all class I alleles with phenotypic
frequency of .2%, and LILRB2-HLA binding scores as
continuous variables. The LILRB2-HLA binding effect on viral
control was tested first in a categorical analysis comparing
controllers to noncontrollers. The A, B and ABC binding scores
demonstrated significant independent effects on viral control in
white patients (OR=1.2–1.3 for a change of 0.1 binding unit,
p=10
23–10
218; Table 3), whereas C score did not remain in the
model. The B and ABC binding scores predicted viral control
independently of all individual class I alleles in blacks as well
(OR=1.1–1.3 for a change of 0.1 unit binding, p=10
25–10
26;
Table 4), whereas the A and C binding scores did not stay in the
model. Thus, the inverse correlation between the level of HIV-1
control and LILRB2 binding scores to HLA-B allotypes and to
combined ABC allotypes were consistent in the two racial groups.
Next, we applied the linear regression model with stepwise
selection to the analyses of mVL in the absence of therapy where
mVL was a continuous variable. Among the four binding scores
tested, the B and ABC scores showed significant positive
correlations with mVL independently of the effects of individual
class I alleles in both whites and blacks (Tables S3–S4). This
analysis indicates that an increase in 0.1 unit of the ABC binding
score would predict 0.08 and 0.03 log10 higher mVL in white and
black patients, respectively, independently of individual HLA class
I alleles. This translates to an increase of 1.1 and 0.5 log10 mVL in
whites and blacks, respectively, when comparing patients with the
highest ABC binding score to patients with the lowest score.
To test the stability of the regression models, we applied more
stringent conditions in stepwise selection (p,0.01 and p,0.001 cut-
offs). The B and ABC scores remained significant in the categorical
analysis of viral load control in whites at both cut-offs (Table 3).
While similar stability was observed for the B score in blacks, the
ABC score remained significant in categorical analyses only at the
intermediate cut-off (Table 4). In the continuous analysis of mVL,
the binding scores demonstrated variable stability (Tables S3–S4).
Thus, we observed consistent associations for LILRB2-B and -
ABC binding scores with HIV-1 control tested in both categorical
and continuous analysis of mVL across the two racial groups. The
effects were always less pronounced in the black population
perhaps due to smaller number of individuals in this group. We
also tested for a potential effect of LILRB2-HLA binding level on
disease progression using a Cox model in a smaller cohort of
seroconverts (780 whites and 287 blacks), but there was no
significant effect on time to AIDS outcomes (see Materials and
Methods) when individual class I alleles were included as
covariables (data not shown). This negative result may be due to
low statistical power, or the LILRB2 binding effect on HIV-1
control may be outcome-specific and influence viral load only.
Functional effects of LILRB2-HLA interactions
Functional properties of DCs that result from altered LILRB2-
HLA interactions were interrogated using mixed leukocyte
reactions, an assay that measures the ability of DCs to stimulate
antigen-specific T cell responses. Monocyte-derived dendritic cells
(MDDC) were exposed to a panel of different recombinant HLA
molecules, followed by cytokine-mediated maturation and incu-
bation with CFSE-labeled allogeneic T cells according to a
previously described protocol [24]. We observed divergent effects
of different HLA allotypes on proliferative activities of allogeneic T
cells, where the highest levels of proliferation were observed after
Figure 1. LILRB2 binding strength and odds ratios for viral load
control for individual HLA-B alleles. The data plotted includes only
alleles with significant association (p,0.05) for white (A) and black (B)
patients in a univariate analysis for each HLA-B allele. Spearman
correlation coefficient and p values are indicated.
doi:10.1371/journal.pgen.1004196.g001
Table 1. Spearman correlation between LILRB2 binding
strength and odds ratios of HLA alleles (p,0.05) for viral load
control in HIV-1-infected individuals.
N (alleles) r p
Whites (N=2685)
HLA-A 10 0.05 0.9
HLA-B 14 0.64 0.01
HLA-C 9 20.38 0.3
Blacks (N=1306)
HLA-A 6 0.09 0.9
HLA-B 8 0.24 0.6
HLA-C 5 20.30 0.6
doi:10.1371/journal.pgen.1004196.t001
LILRB2-HLA Interaction and HIV-1 Control
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binding to LILRB2, and the lowest proliferative activities were
observed following exposure to HLA class I molecules with
strongest binding to LILRB2 (Figures 3A and S2). These data are
consistent with an inverse relationship between MDDC function
and corresponding LILRB2-HLA binding strength (Figure 3B).
siRNA-mediated knockdown of LILRB2 surface expression on
MDDC (Figure S1) reversed inhibitory effects of HLA class I
allotypes in a reciprocal hierarchical order (Figures 3A and S2),
leading to a positive association between fold changes in MDDC
function after LILRB2 knockdown and corresponding LILRB2-
HLA binding scores (Figure 3C). However, inhibitory effects of
two specific HLA class I allotypes (HLA-A*02:01 and -C*01:02)
on DC function were not significantly affected by LILRB2
knockdown, suggesting that these HLA allotypes may interact with
additional, as of yet unidentified immunoregulatory receptors on
DCs. In contrast to antigen-presentation properties, secretion of
TNFa, IL-6 or IL-12p70 by MDDC was not significantly
influenced by LILRB2-HLA-B interactions (Figure S3). Together,
these results suggest that LILRB2-HLA impact immune control of
HIV-1 through alterations of the functional antigen-presenting
properties of DCs.
Discussion
Among all human MHC class I alleles, those encoded at the
HLA-B locus have the highest degree of genetic variation and the
dominant influence on HIV/AIDS [5]. Association of particular
HLA-B alleles with HIV-1 infection outcomes is traditionally
linked to the ability of the corresponding allotypes to elicit CTL
responses. This concept is supported by numerous studies of HLA-
restricted CTL responses and viral sequence evolution in carriers
of specific HLA class I alleles [25]. The distinct effect of the HLA-B
locus on cellular immune responses to HIV-1 is likely due to its
greater level of diversity, which results in the presentation of a
broader repertoire of viral peptides that can be presented by HLA-
B allotypes as compared to HLA-A or HLA-C. In addition,
relative resistance of HLA-B to downregulation by HIV-1 viral
protein Nef compared to HLA-A [26] as well as low expression
level of HLA-C were suggested to contribute to the principal role
of the HLA-B locus in HIV-1 disease. However, the structural
polymorphism of HLA-B can also influence its binding to
receptors other than the T cell receptor. Based on the work
presented herein, we propose that variation in binding properties
of HLA-B to the inhibitory myelomonocytic receptor LILRB2 can
contribute to the overall HLA effects on HIV-1 infection outcomes.
The ORs of individual HLA-B alleles determined by comparing
HIV-1 controllers to noncontrollers correlate significantly with
their LILRB2 binding strength in white patients (Figure 1A). A
similar trend was observed in blacks, though not significantly so
(Figure 1B), perhaps due to a smaller number of alleles considered
in blacks (n=8) as compared to whites (n=14). B*81:01, an
allotype present almost exclusively among blacks, appears to be an
outlier in that it binds strongly to LILRB2, but associates with
robust protection against HIV-1. B*81:01 contains an unusual
polymorphism in the a3 domain that dramatically decreases CD8
binding (the same domain that is centrally involved in LILRB2
binding [27]), which may explain in part the protective role of the
B*81:01 in HIV/AIDS [28,29].
A more powerful and direct analysis of a correlation between
LILRB2 binding scores and the level of viremia was conducted by
assigning to each patient a LILRB2 binding score based on their
class I genotypes and correlating these with the mVL determined
from each patient. Our analyses included locus-specific (A, B, C)
scores as well as a global ABC score, which was used as a measure
of average LILRB2 binding to HLA class I overall. Highly
significant correlations between mVL and B and ABC binding
scores were observed in both white and black patients (Table 2).
Two confounding factors may contribute to this strong correlation,
including linkage disequilibrium between the HLA class I loci and
the effects of individual HLA alleles on HIV-1 that are not related
to LILRB2 function. Therefore, regression models with stepwise
selection that included all individual class I alleles and LILRB2
binding scores were employed. The analyses indicated consistent
effects for the B and ABC binding scores, both of which associated
with viral replication tested in a categorical analysis (controllers vs.
noncontrollers, Tables 3–4) and when mVL was used as a
continuous variable in white and black patients (Tables S3–S4).
Whereas the ABC score demonstrated effects similar to the B
score, the B score accounts for all or nearly all of the combined
ABC effect. The OR for viral control was 1.1–1.2 per 0.1 unit
increase of the ABC binding score when comparing controllers to
Figure 2. LILRB2-HLA binding score variations in 2900 white
(A) and 1490 black (B) patients. A, B and C binding scores represent
the sum of the binding scores for two alleles of the corresponding HLA
class I locus. ABC binding score represents the sum of the locus-specific
binding scores with the C scores counted at 1/10 level. Alleles with
undefined scores were assigned the average of the scores for a given
locus. Box and Whisker plots reflect median, the 25% and 75%
percentiles and the minimum and maximum of all data.
doi:10.1371/journal.pgen.1004196.g002
Table 2. Spearman correlation between LILRB2 binding
strength and mVL in HIV-1-infected individuals.
Nr p
Whites 2900
LILRB2-A 0.01 8E-01
LILRB2-B 0.24 1E-38
LILRB2-C 20.12 2E-10
LILRB2-ABC 0.21 3E-30
Blacks 1490
LILRB2-A 0.01 7E-01
LILRB2-B 0.16 6E-10
LILRB2-C 20.01 6E-01
LILRB2-ABC 0.14 5E-08
doi:10.1371/journal.pgen.1004196.t002
LILRB2-HLA Interaction and HIV-1 Control
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the strength of the LILRB2 binding effect to the strength of
individual HLA allelic effects since the former is based on a
continuous variable (LILRB2 binding score) and the latter on a
dichotomous variable (presence vs. absence of each allele).
However, a comparison of the two patient groups at the extreme
ends of the ABC binding scores (i.e. 10% of patients with the
lowest scores vs. 10% of patients with the highest scores) results
in an OR of 0.3–0.4, which is close to the strength of the protec-
tive effect of B*57 in the same model (OR=0.2–0.3, Tables
3–4).
Neither the A nor the C binding scores demonstrated consistent
effects on viral load when individual class I alleles were included in
the model: the A score remained only in the categorical model
when the least stringent p-value cut-off (,0.05) was used (Table 3),
and the C score was not significant in any of the analyses. Thus,
the negative correlation with mVL that was observed for the C
scores in the univariate model (Table 2) is likely due to effects of
individual alleles that are not related to LILRB2 binding and/or to
linkage disequilibrium between HLA-B and -C.
Notably, the effects of B*27:05, B*57:01 and B*57:03 were
substantially diminished in models that included LILRB2 binding
scores relative to their effects in the absence of this covariable
(Tables 3–4 and S3–S6). Alternatively, the effect of B*81:01 was
not markedly influenced by inclusion of the binding scores in the
model. These results indicate that the protective effects of the B*27
and B*57 alleles may be partially due to low LILRB2 binding, but
this does not appear to be the case for B*81:01.
The correlation between HIV-1 immune control and the
binding strength of LILRB2 to HLA-B allotypes specifically (and
not HLA-A or -C) is difficult to comprehend, since LILRB2 binds
all class I molecules without discrimination [22]. The substantially
greater variation in binding scores for HLA-B as compared to
HLA-A allotypes (Figure 2) may result in a greater influence of
HLA-B on differential immune responses to HIV-1 across infected
individuals. While HLA-C allotypes also show fairly broad
variation in binding scores similar to HLA-B, their lower
expression levels may diminish their effect in regulating myelo-
monocytic cells in HIV-1 infection. Alternatively, HLA-B
expressed on the cell surface may behave in a distinct manner,
for example due to the presence of intracellular cysteines as
suggested by Gruda et al. [30]. Nevertheless, our model with
combined ABC binding scores supports the idea that the average
class I binding strength to LILRB2 can influence viral control, and
the variation in this binding is mostly due to the allotypic diversity
of the HLA-B binding strength to LILRB2.
The effect of LILRB2 binding to HLA class I on immune
response to HIV-1 may be mediated by subsets of DCs expressing
this receptor. Recent work demonstrated that dermal CD14
+ DCs
express both LILRB1 and LILRB2 [31]. These cells, along with
Langerhans cells (LCs) and CD1a
+ dermal DCs, are among the
first immune cells encountered by HIV-1 in sexual transmission.
Table 3. Effect of LILRB2-HLA binding strength and individual class I alleles on viral control (controllers vs. non-controllers) in
white patients.
Whites (N=2685)
LILRB2-A LILRB2-B LILRB2-ABC
Covariate p OR 95%CI Covariate p OR 95%CI Covariate p OR 95%CI
B*57:01 2E-44 0.1 0.1–0.2 LILRB2-B
2 3E-18 1.3 1.2-1.4 B*57:01 7E-12 0.3 0.2–0.4
B*27:05 4E-15 0.3 0.2–0.4 A*01:01 2E-08 2.0 1.6–2.6 LILRB2-ABC
2 9E-12 1.2 1.2–1.3
A*01:01 5E-13 2.4 1.9–3.1 B*44:03 1E-07 2.8 1.9–4.1 A*01:01 1E-10 2.3 1.8–2.9
B*07:02 3E-07 2.0 1.5–2.6 B*57:01 1E-07 0.4 0.3–0.6 B*52:01 5E-07 0.3 0.2–0.5
B*13:02 6E-07 0.4 0.2–0.5 B*52:01 2E-07 0.3 0.2–0.4 C*04:01 5E-07 1.9 1.5–2.5
B*52:01 2E-06 0.3 0.2–0.5 A*25:01 3E-06 0.4 0.3–0.6 B*44:03 2E-06 2.6 1.7–3.8
B*14:02 3E-06 0.5 0.3–0.6 C*04:01 5E-06 1.8 1.4–2.3 B*13:02 3E-05 0.4 0.3–0.6
C*14:02 4E-05 0.4 0.2–0.6 B*40:01 5E-06 2.4 1.7–3.5 A*25:01 3E-05 0.4 0.3–0.7
A*25:01 7E-05 0.4 0.3–0.7 A*02:01 1E-04 1.5 1.2–1.8 B*40:01 4E-05 2.2 1.5–3.2
C*04:01 1E-04 1.6 1.3–2.1 B*49:01 2E-04 2.9 1.6–5.0 B*07:02 3E-04 1.7 1.3–2.2
A*02:01 5E-04 1.5 1.2–1.8 B*38:01 6E-04 2.4 1.5–3.9 A*02:01 4E-04 1.5 1.2–1.8
LILRB2-A
1 7E-04 1.2 1.1–1.4 C*07:02 9E-04 1.6 1.2–2.0 C*14:02 4E-04 0.4 0.2–0.7
B*40:02 9E-04 0.5 0.3–0.7 C*14:02 1E-03 0.4 0.3–0.7 B*49:01 9E-04 2.6 1.5–4.5
B*40:01 3E-03 1.8 1.2–2.6 A*31:01 2E-03 0.6 0.4–0.8 C*05:01 7E-03 1.5 1.1–1.9
A*24:02 2E-02 1.4 1.1–1.8 C*05:01 3E-03 1.5 1.1–2.0 A*68:01 8E-03 1.7 1.2–2.6
B*58:01 2E-02 0.5 0.3–0.9 B*13:02 4E-03 0.6 0.4–0.8 B*38:01 8E-03 2.0 1.2–3.2
B*18:01 2E-02 1.6 1.1–2.3 B*35:02 2E-02 3.3 1.3–8.9 A*24:02 2E-02 1.4 1.1–1.8
A*68:01 2E-02 1.7 1.1–2.5 A*68:02 5E-02 0.6 0.3–1.0 B*27:05 2E-02 0.7 0.5–0.9
B*15:01 4E-02 0.7 0.6–1.0 B*40:02 5E-02 0.6 0.4–1.0
B*35:02 5E-02 2.7 1.0–7.0
Logistic regression model with stepwise selection included all HLA class I alleles with phenotypic frequencies of .2% and one of the A, B, C or ABC binding scores at a
time. The results are shown for the p,0.05 cut-off. The C binding score did not stay in the model. ORs for binding scores reflect a change of 0.1 units.
1stayed in the model with the p,0.01 cut-off but not with the p,0.001 cut-off.
2stayed in the model with the p,0.01 and p,0.001 cut-offs.
doi:10.1371/journal.pgen.1004196.t003
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+ dermal DCs are less efficient at priming CTL
than are LCs, and this difference has been attributed to the lack of
LILRB1/2 expression by LCs [31]. The reduced ability of dermal
CD14
+ DCs to prime CTL was suggested to be due to competition
between LILRB1/2 and CD8 in binding HLA class I, which has
been demonstrated previously [27]. This competition may happen
at the DC-T cell interface where LILRB molecules can interact in
cis with HLA class I [32] on the DC surface, masking class I
molecules from CD8 expressed by the T cells in a manner that
does not necessarily involve inhibitory receptor signaling. Varia-
tion in the strength of LILRB2 binding to HLA class I may
influence the capacity of dermal CD14
+ DCs to prime virus-
specific CTL and explain the effect of LILRB2 binding on viral
load described herein. An alternative mechanism that is supported
by our in vitro data implicates inhibition of DCs after LILRB2
ligation and receptor-mediated signal transduction. Our experi-
ments demonstrate that stronger ligation of LILRB2 on the surface
of MDDC by HLA in trans at an immature stage result in
decreased capacity of these cells to stimulate T cell proliferation
when they mature. This is in line with earlier work suggesting a
regulatory role of the LILRB2 ligation in DC function
[13,14,31,33,34]. Taken together, these data suggest that
LILRB2-HLA interactions influence HIV-1 disease outcomes by
regulating functional properties of DCs and their ability to
generate antigen-specific T cell responses. Such effects are likely to
be amplified by upregulation of LILRB2 surface expression on
DCs in peripheral blood [35,36] and lymph nodes [37] during
progressive HIV-1 infection.
We have recently demonstrated a correlation between HLA-
C expression level and HIV-1 control [38]. Analyses of in vivo
CTL responses indicated that differential HLA-C expression
influences CTL responses to HIV-1 peptides despite its lower
overall cell surface expression relative to that of HLA-A and -B.
The ability of HLA molecules, even those expressed at low
levels, to trigger CTL killing of target cells is supported by in
vitro data showing that as few as three HLA/peptide complexes
can trigger CTL killing [39]. The mechanism of differential
immune responses suggested in the current work is distinct from
allotype-restricted CTL killing and involves regulation of DCs
through engagement of LILRB2 with all allotypes of HLA-A, -
B and -C (i.e. it is not allotype specific, distinguishing it from
CTL killing). Due to the relatively low amount of HLA-C on
the cell surface, the variation in its expression level would
contribute minimally to the diversity of LILRB2 binding to
HLA class I as a whole. Thus, differential HLA-C expression
level has a significant effect on HLA-C-restricted CTL
responses [38], but the overall low expression of HLA-C
compared to HLA-A and -B limits its relative importance in
mediating a response through LILRB2, which binds (at various
levels) to all class I molecules.
The data presented herein underscore the complexity of HLA class I
involvement in control of HIV-1 that goes beyond peptide presentation
to CD8
+ T cells. We propose that the LILRB2-HLA class I interaction
may contribute to the effect of class I on HIV/AIDS through
regulation of DC function. The relative size of this effect compared to
the CTL or NK cell responses requires further investigation.
Materials and Methods
Study subjects
We used data from a total of 5126 HIV-1-infected individuals
from eight US and one European cohorts: the AIDS Linked to
Intravenous Experience (ALIVE), the U.S. military HIV Natural
History Study (DoD HIV NHS), the DC Gay Cohort Study
(DCG), the Multicenter AIDS Cohort Study (MACS), the Multi-
center Hemophilia Cohort Study (MHCS), the Massachusetts
Table 4. Effect of the LILRB2-HLA binding strength and individual class I alleles on viral control in black patients.
Blacks (N=1306)
LILRB2-B LILRB2-ABC
Covariate p OR 95%CI Covariate p OR 95%CI
B*57:03 3E-14 0.3 0.1–0.3 B*57:03 6E-19 0.2 0.1–0.2
LILRB2-B
1 5E-07 1.3 1.1–1.3 A*23:01 4E-06 2.2 1.6–3.2
B*15:10 5E-05 6.2 1.9–6.2 LILRB2-ABC
2 2E-05 1.1 1.1–1.2
A*23:01 2E-04 2.7 1.4–2.7 B*39:10 3E-05 0.2 0.1–0.4
A*36:01 4E-04 9.9 1.9–9.9 A*36:01 3E-05 5.6 2.5–12.7
C*08:04 1E-03 0.6 0.1–0.6 B*81:01 3E-04 0.3 0.2–0.6
B*45:01 4E-03 4.3 1.3–4.3 B*15:10 5E-04 3.0 1.6–5.5
B*35:01 4E-03 2.8 1.2–2.8 B*35:01 1E-03 2.0 1.3–3.0
B*52:01 5E-03 0.8 0.2–0.8 B*45:01 2E-03 2.6 1.4–4.6
B*58:02 6E-03 4.2 1.3–4.2 B*58:02 4E-03 2.4 1.3–4.3
B*81:01 2E-02 0.8 0.2–0.8 C*08:04 1E-02 0.3 0.2–0.8
C*05:01 2E-02 0.9 0.3–0.9 B*52:01 2E-02 0.5 0.2–0.9
C*18:00 3E-02 0.9 0.3–0.9 A*68:02 2E-02 1.7 1.1–2.5
B*39:10 4E-02 1.0 0.1–1.0 A*02:02 5E-02 1.7 1.0–2.8
C*12:03 4E-02 1.0 0.2–1.0
The analysis was similar to the one described in Table 3. The A and C scores did not stay in the model.
1stayed in the model with the p,0.01 and p,0.001 cut-offs.
2stayed in the model with the p,0.01 cut-off but not with the p,0.001 cut-off.
doi:10.1371/journal.pgen.1004196.t004
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City Clinic Cohort (SFCCC), the Study on the Consequences of
Protease Inhibitor Era (SCOPE) and the Swiss HIV Cohort Study
(SHCS). Patients from MACS, MGH, SCOPE and SHCS,
including 2685 white and 1306 black patients, were categorized
in controller and noncontroller groups for the analysis of HLA class
I impact on HIV-1 immune control. Longitudinal viral load data
were available for 2900 white and 1490 black patients from
ALIVE, MACS, MGH, DoD HIV NHS, SCOPE and SHCS.
Seroconversion time and AIDS progression data were known for
780 white and 287 black patients from ALIVE, DCG, MHCS and
SFCCC.
Ethics statement
This study was approved by the protocol review office of the
US National Cancer Institute institutional review board, as well as
by the institutional review board of Massachusetts General
Hospital. Informed consent was obtained at the study sites
from all individuals. Patients’ ethnicities were defined based on
self-report.
HLA genotyping
We performed genotyping of the HLA-A/B/C following the
PCR-SSOP (sequence-specific oligonucleotide probing) typing
protocol and PCR-SBT (sequence based typing) recommended
Figure 3. Impact of LILRB2-HLA interactions on functional properties of dendritic cells. (A) Fold changes in proliferative activities of
allogeneic CD4
+ T cells after exposure to MDDC treated with indicated HLA-A, -B or -C allotypes normalized to MDDC treated with negative beads (N.
Bead), in the absence (white bars, n=5, 8, 5 for HLA-A, -B, -C allotypes, respectively) or presence (gray bars, n=5, 6, 5 for HLA-A, -B, -C allotypes,
respectively) of siRNA-mediated downregulation of LILRB2 surface expression on MDDC. Significance was tested using one-way ANOVA followed by
post-hoc analysis with the Tukey multiple comparison test, or using paired t-tests, as appropriate, (
&p,0.05,
Xp,0.01, *p,0.001). (B): Spearman
correlation between proliferative activities of allogeneic CD4
+ T cells after incubation with MDDC treated with indicated HLA-A, -B and -C allotypes
and corresponding LILRB2-HLA binding scores. (C): Spearman correlation between the ratios of MDDC function in the presence or absence of siRNA-
mediated LILRB2 downregulation, and corresponding LILRB2-HLA-A, -B, -C binding scores.
doi:10.1371/journal.pgen.1004196.g003
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th International Histocompatibility Workshop (http://
www.ihwg.org). All HLA class I genotypes were defined to 4-digit
resolution with the exceptions of A*74:01/2, C*17 and C*18,
which were determined to 2-digits.
LILRB2-HLA binding scores
LILRB2-HLA binding scores were defined in a previously
described experiment [22]. Briefly, a set of LILR-Fc fusion
proteins was tested for binding with LABScreen HLA class I SABs
at a concentration of 0.5, 1 and 2 mM. The level of binding was
assessed by measuring the median fluorescence intensity (MFI) of
the LILR-Fc bound to the beads using appropriate normalizations,
which included subtraction of the Fc-negative control MFI and
division of the result by the MFI of W6/32 (monoclonal anti-HLA
class I antibodies recognizing b2m-associated HLA molecules).
The normalized values were assigned to each HLA allotype as
binding scores. Each binding score is a function of avidity of
bivalent LILRB2-Fc for HLA, which in turn depends on the
affinity of monomeric LILRB to HLA. Therefore, the binding
score can be used as a quantitative characteristic of the strength of
LILR-HLA interactions. The relative LILR binding to different
HLA allotypes was similar at each of the LILR concentrations
tested (Figure S4). This consistency between LILR concentrations
assured us that the difference in MFIs between the allotypes is
mainly due to difference in binding strength, and is not an
experimental artifact. The 1 mM concentration results were
chosen as a representative dataset. Among the HIV-1-infected
patients used for the analyses, frequencies of the HLA-A/B/C
alleles with unknown binding scores were 2/11/24% in white and
8/13/39% in black patients. To avoid power loss, we used mean
values for the corresponding locus for each genotype with
unknown score. The pairs of alleles A*74:01/2 and B*81:01 differ
only at the signal peptide, therefore, they were treated as
individual alleles in the context of LILRB2 binding.
Mixed leukocyte reactions
Monocyte Derived Dendritic Cells (MDDC) were prepared as
described previously. Briefly, 2 610
8 PBMCs were plated in 5%
pooled human serum medium and incubated during 60 min at
37uC to adhere monocytes. After discarding non-adherent cells,
monocytes were differentiated into MDDC in the presence of
RPMI 1640 medium supplemented with 50 mg/ml of GM-CSF
(Amgen) and 10% fetal bovine serum. On day 5, immature MDDC
were gently detached using PBS with 0.5% BSA and 2 mM EDTA,
harvested and plated at 4x10
5 cell/well in a round-bottom 96-well
plate (Costar). Next, cells were incubated with beads coated with
selectedHLA-B allotypes, or uncoated controlbeads (One Lambda)
for 30 min at 37uC, washed, and subsequently matured in the
presence of a previously described cytokine cocktail containing
5 ng/ml IL-1b, 5 ng/ml TNFa,1mg/ml PGE-2 and 0.15 mg/ml
IL-6. After 16 hours, mature MDDC were mixed with negatively-
isolated CFSE-labeled allogeneic T cells at a DC:T cell ratio of
1:100 for mixed lymphocyte reactions. Allogeneic T cell prolifer-
ation was determined after 6 days in culture by investigators blinded
towards the added HLA class I molecules, using an LSRFortessa
flow cytometer (Becton Dickinson).
Cytokine secretion assays
To analyze cytokine secretion, immature MDDC were
prepared and treated with HLA class I molecules as described
above and then matured using 5 mg/ml CL097 (InvivoGen) in the
presence of 5 mg/ml brefeldin A. After 20 hours, cells were fixed
and permeabilized, stained with antibodies recognizing intracel-
lular IL-12p70, TNFa and IL-6, and processed to flow cytometric
acquisition by investigators blinded towards the added HLA class I
allotypes.
siRNA-mediated gene knockdown
10
6 MDDC were suspended in 300 ml Optimem (Gibco) in the
presence of 2 nmol of either LILRB2-specific (LILRB2-siRNA) or
scramble control siRNA (sc-siRNA) pools (On-TARGET plus
SMARTpool, Dharmacon) and transferred to a 4-mm electropo-
ration cuvette (Bio-Rad Laboratories). Cells were left on ice for
10 min, electroporated (900 V, 0.75 msec square wave; Genepul-
ser Xcell; Bio-Rad Laboratories), and transferred back to culture
medium for another 24 to 48 hours. Efficiency of specific siRNA-
mediated LILRB2 knockdown was determined by flow cytometry
using an anti-LILRB2 antibody (clone 42D1, Biolegend).
Statistical analysis
We used SAS 9.1 (SAS Institute) for data management and
statistical analyses. The effect of HLA alleles on viral control was
determined by categorical analysis of the allelic frequencies in
HIV-1 controllers and noncontrollers. Corresponding ORs were
calculated using logistic regression model with SAS procedure
PROC LOGISTIC. Relationships between viral loads and
LILRB2-HLA binding scores were analyzed by the Spearman
correlation test using PROC CORR. Permutation analysis was
done by random assignment of binding scores to HLA-B alleles
(10,000 times) and testing the probability of significant Spearman
correlation of the binding scores with ORs with p,0.05.
LILRB2 binding scores as continuous variables and presence
versus absence of all individual HLA class I alleles of frequency
$2% were included with stepwise selection in all regression
models. Results in the tables are for the models using a threshold
of a two-sided p value ,0.05 for inclusion of a covariate as a
significant independent effect. The stability of regression models
was tested using more stringent thresholds of p,0.01 and
p,0.001 for inclusion in the model. The results for the binding
scores are indicated in the footnotes to the tables.
Cox proportional hazards model was applied to perform AIDS
progression analysis by using PROC PHREG. For this, we
estimated the seroconversion date as the midpoint between the
first positive and the last negative HIV-1 antibody test (mean
interval, 0.79 years; range, 0.07 to 3.0 years). Four end points
reflecting disease progression (AIDS outcomes) were evaluated:
time to CD4,200 cells/ml; progression to AIDS according to the
1987 definition by the Centers for Disease Control and Prevention
(CDC, [40]); progression to AIDS according to the 1993 definition
by CDC; and AIDS-related death [41].
Data of in vitro experiments were presented as Box and Whisker
plots, reflecting the median, minimum, maximum and the 25
th
and 75
th percentiles. Significance was tested using one-way
ANOVA followed by post-hoc analysis with the Tukey multiple
comparison test, or using paired t-tests, as appropriate.
Supporting Information
Figure S1 siRNA-mediated downregulation of LILRB2 on
monocyte-derived dendritic cells. Histogram reflects LILRB2
surface expression 48 hours after transfection with LILRB2-
specific or control siRNA.
(PDF)
Figure S2 Impact of LILRB2-HLA interactions on functional
properties of dendritic cells. Representative dot plots reflecting
proliferative activities of allogeneic CD4
+ T cells after incubation
with MDDC exposed to indicated HLA-A (A), -B (B) and -C (C)
allotypes, in the absence or presence of siRNA-mediated
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indicate the proportion of proliferating CD4
+ T cells.
(PDF)
Figure S3 HLA-B allotypes do not differentially affect cytokine
secretionofMDDC.DatareflectproportionsofMDDCsecretingthe
indicated cytokines after exposure to different HLA-B molecules.
Cumulative results from 4 independent experiments are shown.
(PDF)
Figure S4 The relative LILR binding strength to different HLA
allotypes was similar at each of the LILR concentrations tested.
Spearman correlations between the binding scores of 3 different
tested concentrations of LILRB2 to HLA-A (A), -B (B) and -C (C)
allotypes. Spearman correlation coefficient and p values are
indicated on graphs. (D) Analysis of LILRB2 binding scores at the
concentrations of 0.5, 1 and 2 mM to protective (blue) and high
risk (red) HLA-B allotypes.
(PDF)
Table S1 HLA class I allele-specific LILRB1 and LILRB2
binding scores and corresponding odds ratios (OR) for viral load
control as determined in a univariate model for each correspond-
ing allele. ORs were not defined for some HLA alleles that cannot
be genotyped (C*17:01 and C*18:02) and for alleles that were not
present in the controller groups or in the whole population.
Analysis for the combined cohort (All) was adjusted for race.
(PDF)
Table S2 Spearman correlation between LILRB1 binding
strength and odds ratios (p,0.05) for viral load control in HIV-
1-infected individuals.
(PDF)
Table S3 Effect of the LILRB2-HLA binding strength and
individual class I alleles on mVL in white patients. Linear
regression models with stepwise selection included all HLA class I
alleles with phenotypic frequencies of .2% and one of the A, B, C
or ABC binding scores at a time. The results are shown for the
p,0.05 cut-off. The A and C scores did not stay in the model.
(PDF)
Table S4 Effect of the LILRB2-HLA binding strength and
individual class I alleles on mVL in black patients. The analysis
was similar to the one described in Table S3. The results are
shown for the p,0.05 cut-off. The A and C scores did not stay in
the model.
(PDF)
Table S5 Effect of individual class I alleles on viral control
(controllers vs. noncontrollers). Logistic regression model with
stepwise selection included all HLA class I alleles with phenotypic
frequencies of .2%. The results are shown for the p,0.05 cut-off.
(PDF)
Table S6 Effect of individual HLA class I alleles on mVL. Linear
regression model with stepwise selection included all HLA class I
alleles with phenotypic frequencies of .2%. The results are shown
for the p,0.05 cut-off.
(PDF)
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